Roth Capital Downgrades PTC Therapeutics To Neutral

Analysts at Roth Capital downgraded

from Buy to Neutral. The price target for PTC Therapeutics has been lowered from $75.00 to $63.00. PTC Therapeutics shares have gained 248.85 percent over the past 52 weeks, while the S&P 500 index has surged 13.21 percent in the same period. PTC Therapeutics' shares fell 4.34 percent to $58.20 in after-hours trading.